Progenics Pharmaceuticals (PGNX) 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
	Mar. 31, 2014	2-May-14	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'PROGENICS PHARMACEUTICALS INC	'	'
Entity Central Index Key	'0000835887	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$171,517,805
Entity Common Stock, Shares Outstanding	'	69,555,634	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'Q1	'	'
Document Type	'10-Q	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Mar-14	'	'

CONSOLIDATED_BALANCE_SHEETS_Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$94,036	$65,860
Accounts receivable, net	817	2,879
Other current assets	2,845	1,943
Total current assets	97,698	70,682
Auction rate securities	2,208	2,208
Fixed assets, at cost, net of accumulated depreciation and amortization	2,280	2,413
Intangible assets, net (Note 5)	31,378	31,379
Goodwill	7,702	7,702
Other assets	158	157
Total assets	141,424	114,541
Current liabilities:	'	'
Accounts payable and accrued expenses	3,981	6,512
Other current liabilities	115	115
Total current liabilities	4,096	6,627
Contingent consideration liability	16,200	15,700
Deferred tax liability - long term	12,321	12,321
Other liabilities	913	914
Total liabilities	33,530	35,562
Commitments and contingencies (Note 10)	'	'
Stockholders' equity:	'	'
Preferred stock, $.001 par value; 20,000,000 shares authorized; issued and outstanding - none	0	0
Common stock, $.0013 par value; 160,000,000 shares authorized; issued - 69,775,404 in 2014 and 61,025,404 in 2013	91	79
Additional paid-in capital	586,726	548,510
Accumulated deficit	-475,990	-466,677
Accumulated other comprehensive loss	-192	-192
Treasury stock, at cost (200,000 shares in 2014 and 2013)	-2,741	-2,741
Total stockholders' equity	107,894	78,979
Total liabilities and stockholders' equity	$141,424	$114,541

CONSOLIDATED_BALANCE_SHEETS_Un1

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Stockholders' equity:	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, authorized	160,000,000	160,000,000
Common stock, issued	69,775,404	61,025,404
Common stock, shares outstanding (in shares)	69,575,404	60,825,404
Treasury stock, shares	200,000	200,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Royalty income	$735	$1,157
Collaboration revenue	1,049	853
Research grants	0	198
Other revenues	31	18
Total revenues	1,815	2,226
Expenses:	'	'
Research and development	6,934	8,721
License fees - research and development	90	70
Royalty expense	82	116
General and administrative	3,890	4,314
Depreciation and amortization	144	277
Total expenses	11,140	13,498
Operating loss	-9,325	-11,272
Other income:	'	'
Interest income	12	14
Total other income	12	14
Net loss	($9,313)	($11,258)
Net loss per share - basic and diluted	($0.15)	($0.22)
Weighted-average shares - basic and diluted	63,958	50,116

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME [Abstract]	'	'
Net loss	($9,313)	($11,258)
Other comprehensive income:	'	'
Net change in unrealized loss on auction rate securities	0	8
Total other comprehensive income	0	8
Comprehensive loss	($9,313)	($11,250)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total
In Thousands, except Share data
Balance, beginning at Dec. 31, 2012	$61	$493,613	($424,105)	($260)	($2,741)	$66,568
Balance, beginning (in shares) at Dec. 31, 2012	46,765,000	'	'	'	-200,000	'
Net loss	'	'	-11,258	'	'	-11,258
Other comprehensive income	'	'	'	8	'	8
Compensation expenses for share-based payment arrangements	'	749	'	'	'	749
Acquisition of subsidiary, net of issuance costs	6	11,214	'	'	'	11,220
Stock Issued During Period, Shares, Acquisitions	4,472,000	'	'	'	'	'
Exercise of stock options	0	3	'	'	'	3
Exercise of stock options (in shares)	1,000	'	'	'	'	'
Balance, ending at Mar. 31, 2013	67	505,579	-435,363	-252	-2,741	67,290
Balance, ending (in shares) at Mar. 31, 2013	51,238,000	'	'	'	-200,000	'
Balance, beginning at Dec. 31, 2013	79	548,510	-466,677	-192	-2,741	78,979
Balance, beginning (in shares) at Dec. 31, 2013	61,025,000	'	'	'	-200,000	'
Net loss	'	'	-9,313	'	'	-9,313
Compensation expenses for share-based payment arrangements	'	773	'	'	'	773
Sale of common stock in public offering, net of underwriting discounts and commissions ($2,415) and offering expenses ($380)	12	37,443	'	'	'	37,455
Public Offering shares issued	8,750,000	'	'	'	'	8,750,000
Balance, ending at Mar. 31, 2014	$91	$586,726	($475,990)	($192)	($2,741)	$107,894
Balance, ending (in shares) at Mar. 31, 2014	69,775,000	'	'	'	-200,000	'

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Underwriting discounts and commissions	$2,415
Offering expenses	$380

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($9,313)	($11,258)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	144	277
Gains on sales of fixed assets	-43	-75
Change in contingent consideration liability	500	0
Expenses for share-based compensation awards	773	749
Changes in assets and liabilities:	'	'
Decrease in accounts receivable	2,062	5,402
(Increase) decrease in other current assets	-905	440
(Increase) in other assets	-1	0
(Decrease) in accounts payable and accrued expenses	-2,531	-630
(Decrease) in deferred revenue - current	0	-460
(Decrease) increase in other liabilities	-1	4
Net cash used in operating activities	-9,315	-5,551
Cash flows from investing activities:	'	'
Cash acquired in acquisition of subsidiary	0	1,888
Capital expenditures	-10	-35
Proceeds from sales of fixed assets	46	86
Proceeds from redemption of auction rate securities	0	100
Net cash provided by investing activities	36	2,039
Cash flows from financing activities:	'	'
Equity issuance costs in connection with acquisition of subsidiary	0	-45
Proceeds from public offering of common stock, net of underwriting discounts and commissions and offering expenses	37,455	0
Proceeds from the exercise of stock options	0	3
Net cash provided by (used in) financing activities	37,455	-42
Net increase (decrease) in cash and cash equivalents	28,176	-3,554
Cash and cash equivalents at beginning of period	65,860	58,838
Cash and cash equivalents at end of period	94,036	55,284
Supplemental disclosure of cash flow information:	'	'
Contingent consideration liability	16,200	15,900
Stock acquisition consideration	'	$11,265

Interim_Financial_Statements

Interim Financial Statements	3 Months Ended
	Mar. 31, 2014
Interim Financial Statements [Abstract]	'
Interim Financial Statements	'
	Progenics Pharmaceuticals, Inc. ("Progenics," "we" or "us") develops innovative medicines for oncology. Our clinical development efforts center on late-stage oncology assets. We are conducting a phase 2 clinical trial of our therapeutic candidate for prostate cancer, PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC), and have recently completed a phase 2 trial of 1404 (trofolastat), an imaging agent candidate also for prostate cancer. We are resuming a pivotal phase 2 clinical trial of Azedra™, our ultra-orphan radiotherapy candidate for pheochromocytoma and have determined to move MIP-1095, a small molecule therapeutic candidate for prostate cancer, into clinical development, and expect to file an IND application for it in the U.S. later this year.
	We have licensed our first commercial drug, Relistor® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid induced constipation (OIC), to Salix Pharmaceuticals, Inc., and have partnered other internally-developed or acquired compounds and technologies with third parties. We continue to consider opportunities for strategic collaborations, out-licenses and other arrangements with biopharmaceutical companies involving proprietary research, development and clinical programs, and may in the future also in-license or acquire additional oncology compounds and/or programs.
	We fund our operations to a significant extent from capital-raising. In the first quarter of 2014, we raised $37.5 million in an underwritten public offering of 8.75 million shares of common stock, and entered into an agreement with an investment bank under which we may sell from time to time up to $50 million of our stock. In addition, our current principal sources of revenue from operations are royalty, commercialization milestone and revenue-sharing payments from Salix relating to Relistor. Royalty and milestone payments from Relistor depend on success in development and commercialization, which is dependent on many factors, including Salix's efforts, competition from drugs for the same or similar indications, and decisions by the FDA and other regulatory bodies. The FDA is rescheduling to June 11-12 the meeting of an Advisory Committee, originally announced in June 2013 in response to Salix's appeal of the agency's July 2012 Complete Response Letter in respect of its supplemental New Drug Application for Relistor for treatment of opioid-induced constipation in patients with chronic non-cancer pain. The meeting dates are not official until they are published in the U.S. Government's Federal Register.
	Progenics commenced principal operations in 1988, became publicly traded in 1997 and throughout has been engaged primarily in research and development efforts, establishing corporate collaborations and related activities. Certain of our intellectual property rights are held by wholly owned subsidiaries. All of our operations are conducted at our facilities in Tarrytown, New York. We operate under a single research and development segment.
	Funding and Financial Matters. At March 31, 2014 we held $94.0 million in cash and cash equivalents, an increase of $28.1 million from $65.9 million at 2013 year-end. We expect that this amount will be sufficient to fund operations as currently anticipated beyond one year. We may require additional funding in the future, and if we are unable to conclude favorable collaboration, license, asset sale, capital raising or other financing transactions, we will have to reduce, delay or eliminate spending on some current operations, and/or reduce salary and other overhead expenses, to extend our remaining operations. We expect to continue to incur operating losses for the foreseeable near future.
	Our interim Consolidated Financial Statements included in this report have been prepared in accordance with applicable presentation requirements, and accordingly do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In the opinion of management, these financial statements reflect all adjustments, consisting primarily of normal recurring accruals necessary for a fair statement of results for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. Our interim financial statements should be read in conjunction with the financial statements and notes thereto contained in our 2013 Annual Report on Form 10-K. The year-end consolidated balance sheet data in these financial statements were derived from audited financial statements, but do not include all disclosures required by GAAP.

Acquisition_of_Molecular_Insig

Acquisition of Molecular Insight Pharmaceuticals, Inc	3 Months Ended
	Mar. 31, 2014
Acquisition of Molecular Insight Pharmaceuticals, Inc [Abstract]	'
Acquisition of Molecular Insight Pharmaceuticals, Inc	'
	2.  Acquisition of Molecular Insight Pharmaceuticals, Inc.
	We acquired Molecular Insight in early 2013, and include its operations since the acquisition in our Consolidated Financial Statements. The acquisition consideration included 4,566,210 shares (500,000 of which were placed in an escrow expiring in April 2014) of Progenics common stock in a private transaction not taxable to Progenics. (The closing NASDAQ market price of Progenics' freely transferable common shares on the acquisition date was $2.83 per share.) Under the acquisition agreement, Progenics also agreed to pay to the stockholders potential milestones, in cash or Progenics stock at Progenics' option, of up to $23 million contingent upon achieving specified commercialization events and up to $70 million contingent upon achieving specified sales targets relating to all MIP products. Of the 500,000 placed in escrow, 93,847 shares have been returned to Progenics through March 31, 2014 pursuant to financial adjustment provisions of the agreement. An additional 19,770 shares were returned in April 2014, when the escrow terminated.
	We account for our purchase of Molecular Insight using the acquisition method of accounting. The difference between the estimated fair value of the acquisition consideration paid of $27,165, and fair value of the identifiable net assets of $19,463, represents potential future economic benefits arising from combining Progenics and MIP, and has been recorded as goodwill of $7,702 on the acquisition date.
	During the first quarter of 2013, we incurred $750 in transaction costs related to the acquisition, consisting primarily of legal, accounting and valuation-related expenses, and reduced additional paid-in capital by $45 for acquisition-related equity issuance costs. The transaction costs were recorded in general and administrative expenses in the accompanying consolidated statements of operations. During the first quarters of 2014 and 2013, Molecular's business contributed $1,012 and $329 of revenues and $439 and $3,175 of net loss, respectively.

Revenue_Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2014
Revenue Recognition [Abstract]	'
Revenue Recognition	'
	3.  Revenue Recognition
	The Company recognizes revenue from all sources based on the provisions of the SEC's Staff Accounting Bulletin (SAB) No. 104 (SAB 104) and ASC 605 Revenue Recognition. Under ASC 605, delivered items are separate units of accounting, provided (i) the delivered items have value to a collaborator on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered items is considered probable and substantially in our control. We recognize revenue for payments that are contingent upon performance solely by our collaborator immediately upon the achievement of the defined event if we have no related performance obligations. A separate update to ASC 605 provides guidance on the criteria that should be met when determining whether the milestone method of revenue recognition is appropriate.
	There have been no changes to our revenue recognition accounting policies in the first quarter of 2014. These policies are disclosed in Note 3 to the consolidated financial statements included in our 2013 Annual Report on Form 10-K.
	Under our 2012 agreement with FUJIFILM RI Pharma for the development of 1404 in Japan, we recognized as revenue a $1.0 million payment contingent on execution of the first contract by Fuji with an investigation site for a phase I trial in the first quarter of 2014.
	Under our agreement with CytoDyn Inc. for our PRO 140 program, and Molecular's out-license of its Onalta™ product candidate, we received a total of $3.7 million (including $0.2 million in March 2013) in upfront payments and are eligible for future milestone and royalty payments. In consideration for the upfront payments, we have delivered relevant know-how (including patent rights), inventory and non-reimbursable services. In respect of these deliverables, which have a stand-alone value and represent separate units of accounting, we recognized $0.6 million in the first quarter of 2013.

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2014
Net Loss Per Share [Abstract]	'
Net Loss Per Share	'
	4.  Net Loss Per Share
	Basic net loss per share amounts have been computed by dividing net loss by the weighted-average number of common shares outstanding during the period. As of March 31, 2013, 27,793 shares of unvested restricted stock with non-forfeitable rights to dividends were outstanding; all such shares were vested at the end of the first quarter of 2014. The allocation of 2013 net losses to these participating securities pursuant to the two-class method is not material to both basic and diluted earnings per share. For each of the periods presented below, we reported net losses and, accordingly, potential dilutive common shares were not included in the computation of diluted net loss per share since it would have been anti-dilutive. The calculations of net loss per share, basic and diluted, are as follows:
		Net Loss			Weighted Average Common Shares		Per Share
		(Numerator)			(Denominator)		Amount
					(in thousands)
	Three months ended March 31, 2014
	Basic and diluted	$	(9,313	)		63,958	$	(0.15	)
	Three months ended March 31, 2013
	Basic and diluted	$	(11,258	)		50,116	$	(0.22	)
	For these periods, anti-dilutive common shares excluded from diluted per share amounts consist of the following:
		Three Months Ended March 31,
		2014					2013
		Weighted Average			Weighted		Weighted Average			Weighted
		Number			Average		Number			Average
		(in thousands)			Exercise Price		(in thousands)			Exercise Price
	Options		5,868		$	10.74		5,728		$	12.37
	Restricted stock		-					28
	Total		5,868					5,756

InProcess_Research_and_Develop

In-Process Research and Development and Goodwill	3 Months Ended
	Mar. 31, 2014
In-Process Research and Development and Goodwill [Abstract]	'
In-Process Research and Development and Goodwill [Text Block]	'
	5.  In-Process Research and Development and Goodwill
	The fair values of in-process research and development (IPR&D) acquired in business combinations are capitalized. The Company utilizes the "income method," which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&D intangible assets which are determined to have a decline in their fair value are adjusted downward and an expense is recognized as part of the general and administrative expenses in the Consolidated Statements of Operations. These are tested at least annually or when a triggering event occurs that could indicate a potential impairment.
	Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company determines whether goodwill may be impaired by comparing the fair value of the reporting unit, calculated as the product of shares outstanding and the share price as of the end of a period, to its carrying value. No goodwill impairment has been recognized as of March 31, 2014 or 2013. The Company has determined that it has only one reporting unit, which includes the acquired Molecular Insight.
	The following tables reflect the components of the finite lived intangible assets as of March 31, 2014 and December 31, 2013:
	As of March 31, 2014	Gross		Accumulated		Net Carrying
		Amount		Amortization		Value
	Finite lived intangible assets	$	21	$	3	$	18
	Total	$	21	$	3	$	18
	As of December 31, 2013	Gross		Accumulated		Net Carrying
		Amount		Amortization		Value
	Finite lived intangible assets	$	21	$	2	$	19
	Total	$	21	$	2	$	19
	The weighted-average remaining life of the finite lived intangible assets was approximately five years at March 31, 2014 and December 31, 2013.
	Amortization expense is calculated on a straight-line basis over the estimated useful life of the asset. Amortization expense for the three months ended March 31, 2014 was $1. Estimated amortization expense related to intangible assets existing as of March 31, 2014 is approximately $4 annually for each of the succeeding five years.
	The following tables summarize the activity related to the Company's goodwill and indefinite lived IPR&D:
		Goodwill		IPR&D
	Balance at January 1, 2014	$	7,702	$	31,360
	Impairment		-		-
	Balance at March 31, 2014	$	7,702	$	31,360
		Goodwill		IPR&D
	Balance at January 1, 2013	$	-	$	-
	Increase related to acquisition		7,702		32,300
	Balance at March 31, 2013	$	7,702	$	32,300

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	6.  Fair Value Measurements
	We record auction rate securities at fair value in the accompanying Consolidated Balance Sheets in accordance with ASC 320 Investments – Debt and Equity Securities. The change in the fair value of these investments is recorded as a component of other comprehensive loss (see Note 3. Summary of Significant Accounting Policies - Fair Value Measurements in the notes to consolidated financial statements included in our 2013 Annual Report on Form 10-K). We also record the contingent consideration liability resulting from the MIP acquisition at fair value in accordance with ASC 820-10-50.
	The following tables present our money market funds and auction rate securities and contingent consideration liability measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy:
							Fair Value Measurements at March 31, 2014
			Balance at				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs		Significant Unobservable Inputs
			31-Mar-14				(Level 1)				(Level 2)		(Level 3)
	Assets:
	Money market funds		$	85,373			$	85,373			$	-	$	-
	Auction rate securities			2,208				-				-		2,208
	Total Assets		$	87,581			$	85,373			$	-	$	2,208
	Liability:
	Contingent consideration		$	16,200			$	-			$	-	$	16,200
	Total Liability		$	16,200			$	-			$	-	$	16,200
							Fair Value Measurements at December 31, 2013
			Balance at				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs		Significant Unobservable Inputs
			31-Dec-13				(Level 1)				(Level 2)		(Level 3)
	Assets:
	Money market funds		$	60,364			$	60,364			$	-	$	-
	Auction rate securities			2,208				-				-		2,208
	Total Assets		$	62,572			$	60,364			$	-	$	2,208
	Liability:
	Contingent consideration		$	15,700			$	-			$	-	$	15,700
	Total Liability		$	15,700			$	-			$	-	$	15,700
	At March 31, 2014 we held $2,208 in auction rate securities which are classified as Level 3. The fair value of these securities includes U.S. government subsidized securities collateralized by student loan obligations, with maturities greater than 10 years. We will not realize cash in respect of the principal amount of these securities until the issuer calls or restructures the security, the security reaches any scheduled maturity and is paid, or a buyer outside the auction process emerges. We have to date received all scheduled interest payments on these securities, which, in the event of auction failure, are reset according to contractual terms in the governing instruments.
	The valuation of auction rate securities we hold is based on Level 3 unobservable inputs which consist of our internal analysis of (i) timing of expected future successful auctions or issuer calls of the securities, (ii) collateralization of underlying assets of the security and (iii) credit quality of the security. Significant increases or decreases in the redemption period or discount rates would result in a significantly lower or higher, respectively, fair value measurement. The temporary impairment amount associated with these securities, the duration of which is greater than 12 months, remained unchanged from year-end 2013 at $192, which is reflected as part of accumulated other comprehensive loss on our accompanying Consolidated Balance Sheets. Based on our re-evaluation for this quarter, we continue to believe that we have the ability to hold these securities until recovery of fair value. Due to the uncertainty related to the liquidity in the auction rate security market and therefore when individual positions may be liquidated, we have classified these auction rate securities as long-term assets on our accompanying Consolidated Balance Sheets. We continue to monitor markets for our investments and consider the impact, if any, of market conditions on the fair market value of our investments. We do not believe the carrying values of our investments are other than temporarily impaired and therefore expect the positions will eventually be liquidated without significant loss.
	The estimated fair value of the contingent consideration liability of $16.2 million as of March 31, 2014, represents future potential milestone payments to former MIP stockholders. The Company considers this liability a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flow and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs were the probabilities of achieving regulatory approval of the development projects and subsequent commercial success, and discount rates. Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement, respectively. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement, respectively. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the Consolidated Statements of Operations.
	The following table presents quantitative information pertaining to the March 31, 2014 fair value measurement of the Level 3 inputs. The assumptions remained unchanged since December 31, 2013:
		Fair Value as			Fair Value as of December 31,			Valuation Technique		Unobservable Input		Range
		of March 31,			2013							(Weighted Average)
		2014
	Asset:
	Auction rate securities	$	2,208		$	2,208		Discounted cash flow model		Redemption period		5 to 15 years
												(6 years)
										Discount rate		0.25% - 3.00% (1.55%)
	Contingent consideration
	liability:
	Azedra commercialization	$	2,300		$	2,300		Probability adjusted discounted cash flow model		Probability of success		40%
										Period of milestone expected achievement		2017
										Discount rate		10%
	1404 commercialization	$	2,100		$	2,000		Probability adjusted discounted cash flow model		Probability of success		31%
										Period of milestone expected achievement		2018
										Discount rate		10%
	MIP-1095 commercialization	$	500		$	500		Probability adjusted discounted cash flow model		Probability of success		19%
										Period of milestone expected achievement		2021
										Discount rate		10%
	Net sales targets	$	11,300		$	10,900		Monte-Carlo simulation		Probability of success		19% - 40%
												-32.80%
										Period of milestone expected achievement		2018 - 2022
										Discount rate		12.50%
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
			Asset – Auction Rate Securities
			Fair Value Measurements Using Significant
			Unobservable Inputs
			(Level 3)
			For the Three Months Ended March 31,
	Description		2014				2013
	Balance at beginning of period		$	2,208			$	3,240
	Transfers into Level 3			-				-
	Total realized/unrealized gains (losses)
	Included in net income (loss)			-				-
	Included in comprehensive income (loss)			-				8
	Settlements			-				(100	)
	Balance at end of period		$	2,208			$	3,148
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date		$	-			$	-
		Liability – Contingent Consideration
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
		For the Three Months Ended March 31,
Description		2014				2013
Balance at beginning of period		$	15,700			$	-
Fair value of contingent consideration – acquisition of Molecular Insight			-				15,900
Fair value change to contingent consideration included in net loss			500				-
Balance at end of period		$	16,200			$	15,900
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period		$	500			$	-

Accounts_Receivable

Accounts Receivable	3 Months Ended
	Mar. 31, 2014
Accounts Receivable [Abstract]	'
Accounts Receivable	'
	7.  Accounts Receivable
	Accounts receivable represent amounts due to Progenics from collaborators, royalty obligations owing to us, and sales of research reagents, and at the below dates amounted to:
		31-Mar-14			31-Dec-13
	Collaborators	$	49		$	12
	Royalties		750			2,862
	Other		27			12
			826			2,886
	Less, allowance for doubtful accounts		(9	)		(7	)
	Total	$	817		$	2,879

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Accounts Payable and Accrued Expenses	'
	8.  Accounts Payable and Accrued Expenses
	The carrying value of our accounts payable and accrued expenses approximates fair value, as it represents amounts due to vendors and employees which will be satisfied within one year. Accounts payable and accrued expenses at the below dates amounted to:
		31-Mar-14		31-Dec-13
	Accrued consulting and clinical trial costs	$	1,593	$	2,672
	Accrued payroll and related costs		875		2,123
	Restructuring accrual		212		-
	Legal and professional fees		880		608
	Accounts payable		307		793
	Other		114		316
	Total	$	3,981	$	6,512

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2014
Restructuring [Abstract]	'
Restructuring	'
	9. Restructuring
	Our most recent headcount reduction occurred in the first quarter of 2014, resulting in a $0.4 million restructuring obligation for this year, of which $0.2 million was paid through the end of the first quarter. In the first quarter of 2013 an additional headcount reduction resulted in a $1.5 million restructuring obligation, which was paid that year.
	Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets and research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.
		Severance and Related Benefits			Other Exit Costs		Contract Termination Costs		Total Restructuring Accrual
	Balance at December 31, 2013	$	-		$	-	$	-	$	-
	Additions, net		358			-		-		358
	Payments		(146	)		-		-		(146	)
	Balance at March 31, 2014	$	212		$	-	$	-	$	212
		Severance and Related Benefits			Other Exit Costs		Contract Termination Costs		Total Restructuring Accrual
	Balance at December 31, 2012	$	813		$	-	$	-	$	813
	Additions, net		1,477			-		-		1,477
	Payments		(854	)		-		-		(854	)
	Balance at March 31, 2013	$	1,436		$	-	$	-	$	1,436

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	10.  Commitments and Contingencies
	In the ordinary course of our business, we enter into agreements with third parties, such as business partners, clinical sites and suppliers, that include usual and customary indemnification provisions. We generally reciprocally agree to indemnify, hold harmless and reimburse indemnified parties for losses suffered or incurred with respect to products or product candidates, use of such products or other actions taken or omitted by the parties. The maximum potential amount of future payments we could be required to make under these indemnification provisions is frequently not limited. We have not incurred material costs to defend lawsuits or settle claims related to these provisions. As a result, the estimated fair value of liabilities relating to indemnification provisions is minimal. We have no liabilities recorded for these provisions as of March 31, 2014 and December 31, 2013.
	Progenics is a party to a proceeding brought by a former employee complaining that the Company violated the anti-retaliation provisions of the federal Sarbanes-Oxley law by terminating the former employee. The Company believes the former employee's claims are without merit and is contesting the matter vigorously. The federal District Court hearing the case issued in July 2013 an order denying our motion for summary judgment dismissing the former employee's complaint, making it likely that the proceeding will continue to trial. Given the inherent uncertainty attendant to the proceeding, it is not possible at this time to estimate the likelihood or potential magnitude of any outcome, and we have accordingly not recorded any associated liability in these Consolidated Financial Statements.
	Progenics in October 2013 commenced an arbitration with Ono under the provisions of the parties' License Agreement, following a communication from Ono that it has determined to discontinue development of subcutaneous Relistor in Japan because of "commercial concerns" that Ono contends would permit it to cease development and terminate the Agreement. Under our Agreement with Ono, Ono may cease development of subcutaneous Relistor only if it terminates the License Agreement, which it may do unilaterally only if Progenics is in material default. Progenics is not in default under the Agreement, but Ono has asked the arbitration panel to declare that it is and to rescind the Agreement, both of which Progenics believes are without merit and is opposing.  Ono has not terminated the Agreement.

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Net Loss Per Share [Abstract]	'
Calculation of net loss per share, basic and diluted	'
		Net Loss			Weighted Average Common Shares		Per Share
		(Numerator)			(Denominator)		Amount
					(in thousands)
	Three months ended March 31, 2014
	Basic and diluted	$	(9,313	)		63,958	$	(0.15	)
	Three months ended March 31, 2013
	Basic and diluted	$	(11,258	)		50,116	$	(0.22	)
Schedule of antidilutive common shares excluded from computation of diluted earnings per share	'
	For these periods, anti-dilutive common shares excluded from diluted per share amounts consist of the following:
		Three Months Ended March 31,
		2014					2013
		Weighted Average			Weighted		Weighted Average			Weighted
		Number			Average		Number			Average
		(in thousands)			Exercise Price		(in thousands)			Exercise Price
	Options		5,868		$	10.74		5,728		$	12.37
	Restricted stock		-					28
	Total		5,868					5,756

InProcess_Research_and_Develop1

In-Process Research and Development and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2014
In-Process Research and Development and Goodwill [Abstract]	'
Components of finite lived intangible assets [Text Block]	'
	The following tables reflect the components of the finite lived intangible assets as of March 31, 2014 and December 31, 2013:
	As of March 31, 2014	Gross		Accumulated		Net Carrying
		Amount		Amortization		Value
	Finite lived intangible assets	$	21	$	3	$	18
	Total	$	21	$	3	$	18
	As of December 31, 2013	Gross		Accumulated		Net Carrying
		Amount		Amortization		Value
	Finite lived intangible assets	$	21	$	2	$	19
	Total	$	21	$	2	$	19
Activity related to goodwill and indefinite lived intangible assets [Text Block]	'
	The following tables summarize the activity related to the Company's goodwill and indefinite lived IPR&D:
		Goodwill		IPR&D
	Balance at January 1, 2014	$	7,702	$	31,360
	Impairment		-		-
	Balance at March 31, 2014	$	7,702	$	31,360
		Goodwill		IPR&D
	Balance at January 1, 2013	$	-	$	-
	Increase related to acquisition		7,702		32,300
	Balance at March 31, 2013	$	7,702	$	32,300

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Assets and liabilities measured at fair value on recurring basis	'
	The following tables present our money market funds and auction rate securities and contingent consideration liability measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy:
							Fair Value Measurements at March 31, 2014
			Balance at				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs		Significant Unobservable Inputs
			31-Mar-14				(Level 1)				(Level 2)		(Level 3)
	Assets:
	Money market funds		$	85,373			$	85,373			$	-	$	-
	Auction rate securities			2,208				-				-		2,208
	Total Assets		$	87,581			$	85,373			$	-	$	2,208
	Liability:
	Contingent consideration		$	16,200			$	-			$	-	$	16,200
	Total Liability		$	16,200			$	-			$	-	$	16,200
							Fair Value Measurements at December 31, 2013
			Balance at				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs		Significant Unobservable Inputs
			31-Dec-13				(Level 1)				(Level 2)		(Level 3)
	Assets:
	Money market funds		$	60,364			$	60,364			$	-	$	-
	Auction rate securities			2,208				-				-		2,208
	Total Assets		$	62,572			$	60,364			$	-	$	2,208
	Liability:
	Contingent consideration		$	15,700			$	-			$	-	$	15,700
	Total Liability		$	15,700			$	-			$	-	$	15,700
Quantitative information for fair value measurement of Level 3	'
	The following table presents quantitative information pertaining to the March 31, 2014 fair value measurement of the Level 3 inputs. The assumptions remained unchanged since December 31, 2013:
		Fair Value as			Fair Value as of December 31,			Valuation Technique		Unobservable Input		Range
		of March 31,			2013							(Weighted Average)
		2014
	Asset:
	Auction rate securities	$	2,208		$	2,208		Discounted cash flow model		Redemption period		5 to 15 years
												(6 years)
										Discount rate		0.25% - 3.00% (1.55%)
	Contingent consideration
	liability:
	Azedra commercialization	$	2,300		$	2,300		Probability adjusted discounted cash flow model		Probability of success		40%
										Period of milestone expected achievement		2017
										Discount rate		10%
	1404 commercialization	$	2,100		$	2,000		Probability adjusted discounted cash flow model		Probability of success		31%
										Period of milestone expected achievement		2018
										Discount rate		10%
	MIP-1095 commercialization	$	500		$	500		Probability adjusted discounted cash flow model		Probability of success		19%
										Period of milestone expected achievement		2021
										Discount rate		10%
	Net sales targets	$	11,300		$	10,900		Monte-Carlo simulation		Probability of success		19% - 40%
												-32.80%
										Period of milestone expected achievement		2018 - 2022
										Discount rate		12.50%
Summary of activities in financial instruments with Level 3 inputs	'
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
			Asset – Auction Rate Securities
			Fair Value Measurements Using Significant
			Unobservable Inputs
			(Level 3)
			For the Three Months Ended March 31,
	Description		2014				2013
	Balance at beginning of period		$	2,208			$	3,240
	Transfers into Level 3			-				-
	Total realized/unrealized gains (losses)
	Included in net income (loss)			-				-
	Included in comprehensive income (loss)			-				8
	Settlements			-				(100	)
	Balance at end of period		$	2,208			$	3,148
	Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date		$	-			$	-
			Liability – Contingent Consideration
			Fair Value Measurements Using Significant
			Unobservable Inputs
			(Level 3)
			For the Three Months Ended March 31,
	Description		2014				2013
	Balance at beginning of period		$	15,700			$	-
	Fair value of contingent consideration – acquisition of Molecular Insight			-				15,900
	Fair value change to contingent consideration included in net loss			500				-
	Balance at end of period		$	16,200			$	15,900
	Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period		$	500			$	-

Accounts_Receivable_Tables

Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2014
Accounts Receivable [Abstract]	'
Accounts Receivable	'
	7.  Accounts Receivable
	Accounts receivable represent amounts due to Progenics from collaborators, royalty obligations owing to us, and sales of research reagents, and at the below dates amounted to:
		31-Mar-14			31-Dec-13
	Collaborators	$	49		$	12
	Royalties		750			2,862
	Other		27			12
			826			2,886
	Less, allowance for doubtful accounts		(9	)		(7	)
	Total	$	817		$	2,879

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Schedule of accounts payable and accrued expenses	'
		31-Mar-14		31-Dec-13
	Accrued consulting and clinical trial costs	$	1,593	$	2,672
	Accrued payroll and related costs		875		2,123
	Restructuring accrual		212		-
	Legal and professional fees		880		608
	Accounts payable		307		793
	Other		114		316
	Total	$	3,981	$	6,512

Restructuring_Tables

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring [Abstract]	'
Activity in restructuring accrual	'
	Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets and research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.
		Severance and Related Benefits			Other Exit Costs		Contract Termination Costs		Total Restructuring Accrual
	Balance at December 31, 2013	$	-		$	-	$	-	$	-
	Additions, net		358			-		-		358
	Payments		(146	)		-		-		(146	)
	Balance at March 31, 2014	$	212		$	-	$	-	$	212
		Severance and Related Benefits			Other Exit Costs		Contract Termination Costs		Total Restructuring Accrual
	Balance at December 31, 2012	$	813		$	-	$	-	$	813
	Additions, net		1,477			-		-		1,477
	Payments		(854	)		-		-		(854	)
	Balance at March 31, 2013	$	1,436		$	-	$	-	$	1,436

Interim_Financial_Statements_D

Interim Financial Statements (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Public Offering [Abstract]	'	'	'	'
Proceeds	$37,455	'	'	'
Public Offering shares issued	8,750,000	'	'	'
Proceeds from future sales of common stock under an agreement with investment bank	50,000	'	'	'
Funding and Financial Matters [Abstract]	'	'	'	'
Cash and cash equivalents at end of period	94,036	55,284	65,860	58,838
Increase in cash and cash equivalents	$28,176	($3,554)	'	'
Minimum number of years cash will fund operations (in years)	'1 year	'	'	'

Acquisition_of_Molecular_Insig1

Acquisition of Molecular Insight Pharmaceuticals, Inc (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Apr. 30, 2014	Dec. 31, 2013	Jan. 18, 2013
Business Acquisition [Line Items]	'	'	'	'	'
Original Shares Issued For Acquisition	'	'	'	'	4,566,210
Shares For Acquisition Held In Escrow	'	'	'	'	500,000
Closing price of Progenics' common shares	'	'	'	'	$2.83
Shares For Acquisition Returned From Escrow	93,847	'	19,770	'	'
Maximum Milestone Payment Specified Commercial Events	$23,000,000	'	'	'	'
Maximum Milestone Payment For Achieving Sales Targets	70,000,000	'	'	'	'
Business Acquisition, Cost of Acquired Entity, Transaction Costs	'	750,000	'	'	'
Equity issuance costs in connection with acquisition of subsidiary	0	45,000	'	'	'
Goodwill	7,702,000	'	'	7,702,000	'
Business Acquisition Transaction Costs Excluded From Pro Forma Information	'	750,000	'	'	'
Molecular Insight Pharmaceuticals Inc [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Business Acquisition Contributed Revenue	1,012,000	329,000	'	'	'
Business Acquisition Contributed Net Loss	439,000	3,175,000	'	'	'
Total acquisition consideration paid	'	'	'	'	27,165,000
Business Acquisition Tangible And Intangible Assets Acquired Liabilities Assumed	'	'	'	'	19,463,000
Goodwill	'	'	'	'	$7,702,000

Revenue_Recognition_Details

Revenue Recognition (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2013
Revenue Recognition [Abstract]	'	'	'	'
License revenue CytoDyn and ITM	'	'	$595,000	'
Upfront license fee received CytoDyn and ITM	200,000	'	'	3,700,000
Milestone Revenue from Fuji	'	$1,000,000	'	'

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net Loss (Numerator) [Abstract]	'	'
Net loss basic and diluted	($9,313)	($11,258)
Weighted Average Common Shares (Denominator) Abstract	'	'
Shares outstanding, basic and diluted (in shares)	63,958,000	50,116,000
Per share amount [Abstract]	'	'
Net loss per share, basic and diluted (in dollars per share)	($0.15)	($0.22)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Unvested restricted stock (in shares)	'	27,793
Weighted Average Number (in shares)	5,868,000	5,756,000
Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Weighted Average Number (in shares)	5,868,000	5,728,000
Weighted Average Exercise Price (in dollars per share)	$10.74	$12.37
Unvested restricted stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Weighted Average Number (in shares)	0	28,000

InProcess_Research_and_Develop2

In-Process Research and Development and Goodwill (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets	'	'	'	'
Finite-Lived Intangible Assets, Gross	$21	'	$21	'
Finite-Lived Intangible Assets, Accumulated Amortization	3	'	2	'
Finite-Lived Intangible Assets, Net, Total	18	'	19	'
Finite-Lived Intangible Asset, Useful Life	'5 years	'	'	'
Estimated amortization of intangible assets for succeeding five years	4	'	'	'
Amortization of Intangible Assets	1	'	'	'
Goodwill and indefinite lived in-process research and development [Abstract]	'	'	'	'
Goodwill	7,702	7,702	7,702	0
Goodwill, Acquired During Period	'	7,702	'	'
Intangible Assets Acquired During Period	'	32,300	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	31,360	32,300	31,360	0
Impairment of Intangible Assets (Excluding Goodwill)	$0	$0	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Contingent consideration liability	$16,200	$15,900	$15,700
Auction rate securities	2,208	'	2,208
Maturity period of US government subsidized securities (in years)	'10 years	'	'
Duration of securities subject to temporary impairment, minimum (in months)	'12 months	'	'
Amount of temporary impairment	192	'	192
Auction Rate Securities [Member]	'	'	'
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]	'	'	'
Balance at beginning of period	2,208	3,240	3,240
Transfers into Level 3	0	0	'
Total gains (losses)	'	'	'
Included in net loss	0	0	'
Included in other comprehensive loss	0	8	'
Settlements at par	0	-100	'
Balance at end of period	2,208	3,148	2,208
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets or liabilities held at the end of the reporting period	0	0	'
Fair Value Measurements, Quantitative Information	'	'	'
Fair Value	2,208	'	2,208
Valuation technique	'Discounted cash flow model	'	'Discounted cash flow model
Auction Rate Securities [Member] | Minimum [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Redemption period	'5 years	'	'5 years
Discount Rate	0.25%	'	0.25%
Auction Rate Securities [Member] | Maximum [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Redemption period	'15 years	'	'15 years
Discount Rate	3.00%	'	3.00%
Auction Rate Securities [Member] | Weighted average [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Redemption period	'6 years	'	'6 years
Discount Rate	1.55%	'	1.55%
Azedra commercialization [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2017	'	'2017
Fair Value	2,300	'	2,300
Valuation technique	'Probability adjusted discounted cash flow model	'	'Probability adjusted discounted cash flow model
Discount Rate	10.00%	'	10.00%
Probability of success	40.00%	'	40.00%
MIP - 1404 commercialization [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2018	'	'2018
Fair Value	2,100	'	2,000
Valuation technique	'Probability adjusted discounted cash flow model	'	'Probability adjusted discounted cash flow model
Discount Rate	10.00%	'	10.00%
Probability of success	31.00%	'	31.00%
MIP-1095 commercialization [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2021	'	'2021
Fair Value	500	'	500
Valuation technique	'Probability adjusted discounted cash flow model	'	'Probability adjusted discounted cash flow model
Discount Rate	10.00%	'	10.00%
Probability of success	19.00%	'	19.00%
Net sales targets [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Fair Value	11,300	'	10,900
Valuation technique	'Monte-Carlo simulation	'	'Monte-Carlo simulation
Discount Rate	12.50%	'	12.50%
Net sales targets [Member] | Minimum [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2018	'	'2018
Probability of success	19.00%	'	19.00%
Net sales targets [Member] | Maximum [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2022	'	'2022
Probability of success	40.00%	'	40.00%
Net sales targets [Member] | Weighted average [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Probability of success	32.80%	'	32.80%
Contingent Consideration Liability [Member]	'	'	'
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]	'	'	'
Balance at beginning of period	15,700	0	0
Total gains (losses)	'	'	'
Fair value of contingent consideration - acquisition of Molecular Insight	0	15,900	'
Fair value change to contingent consideration included in net loss	500	0	'
Balance at end of period	16,200	15,900	'
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets or liabilities held at the end of the reporting period	500	0	'
U.S. Government Subsidized Securities [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Auction rate securities	2,208	'	'
Recurring [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Contingent consideration liability	16,200	'	15,700
Money Market Funds	85,373	'	60,364
Auction rate securities	2,208	'	2,208
Asset, total	87,581	'	62,572
Liability, total	16,200	'	15,700
Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Contingent consideration liability	0	'	0
Money Market Funds	85,373	'	60,364
Auction rate securities	0	'	0
Asset, total	85,373	'	60,364
Liability, total	0	'	0
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Contingent consideration liability	0	'	0
Money Market Funds	0	'	0
Auction rate securities	0	'	0
Asset, total	0	'	0
Liability, total	0	'	0
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Contingent consideration liability	16,200	'	15,700
Money Market Funds	0	'	0
Auction rate securities	2,208	'	2,208
Asset, total	2,208	'	2,208
Liability, total	$16,200	'	$15,700

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	$817	$2,879
Allowance for Doubtful Accounts Receivable	-9	-7
Collaborators [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	49	12
Royalties [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	750	2,862
Other Receivables [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	27	12
Subtotal [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, net	$826	$2,886

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Payable and Accrued Expenses [Abstract]	'	'
Accrued consulting and clinical trial costs	$1,593	$2,672
Accrued payroll and related costs	875	2,123
Restructuring accrual	212	0
Legal and professional fees	880	608
Accounts payable	307	793
Other	114	316
Total	$3,981	$6,512

Restructuring_Details

Restructuring (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Restructuring [Abstract]	'	'
Restructuring accrual of severance and related benefits	$400	$1,500
Restructuring obligation payment	200	'
Activity in restructuring accrual [Roll Forward]	'	'
Balance at beginning of period	0	813
Additions, net	358	1,477
Payments	-146	-854
Balance at end of period	212	1,436
Severance and Related Benefits [Member]	'	'
Activity in restructuring accrual [Roll Forward]	'	'
Balance at beginning of period	0	813
Additions, net	358	1,477
Payments	-146	-854
Balance at end of period	212	1,436
Other Exit Costs [Member]	'	'
Activity in restructuring accrual [Roll Forward]	'	'
Balance at beginning of period	0	0
Additions, net	0	0
Payments	0	0
Balance at end of period	0	0
Contract Termination Costs [Member]	'	'
Activity in restructuring accrual [Roll Forward]	'	'
Balance at beginning of period	0	0
Additions, net	0	0
Payments	0	0
Balance at end of period	$0	$0